FIGO Cancer Report 2015

The FIGO Gynecologic Oncology Committee is pleased to present the second edition of the FIGO Cancer Report. Historically the report was published at each FIGO World Congress as the “Annual Report,” going as far back as 1937, and was composed of survival data from various institutions around the world. Since 2009 the process of collating international incidence and survival data stopped and a new Committee was formed. This Committee initiated the current format of the FIGO Cancer Report and its first edition was presented at the FIGO Congress held in Rome, Italy, in October 2012. The Committee has since established collaboration with the Catalan Institute of Oncology to resurrect the data collection program. This process is now at an advanced stage and a detailed situational analysis of institutions able to provide care to women with gynecological cancers is being conducted as we write this editorial in May 2015. Once the situational analysis is complete the intention is to select 20 or so institutions in low- and middle-income countries to collect incidence, stage, treatment, and survival data. This will give us a global picture of the multiple inequities in cancer care internationally and enable more targeted intervention by organizations such as FIGO. It is our intention to ensure that this, the second edition of the FIGO Cancer Report, is disseminated as widely as possible internationally, and therefore the chapters are available online with Open Access. We are also developing a mobile App of the different criteria for FIGO staging, which will ensure that those with smart phones will have instant access. The chapters contained in the report have either been updated or are new chapters. The new chapters include trophoblastic disease, targeted therapies for gynecological cancer, rehabilitation after treatment for gynecological cancer, psychosexual health in gynecological cancers, palliative care in gynecological cancer, and the future role of molecular staging in gynecological cancer. These six new chapters are added to nine others that include the new staging for ovary, fallopian tube, and peritoneum. Each chapter presents the site specific staging, the rationale behind staging, as well as internationally accepted evidence-based guidelines. All chapters are fully referenced and the quality of the evidence for intervention is graded. Lynette Denny (Chair), Gynecologic Oncologist, South Africa Michael Quinn (Co-Chair), Gynecologic Oncologist, Australia Sergio Pecorelli (Immediate Past Chair), Gynecologic Oncologist, Italy Adriana Bermudez, Gynecologic Oncologist, Argentina Joanna Cain, Gynecologic Oncologist, USA Keiichi Fujiwara, Gynecologic Oncologist, Japan Neville Hacker, Gynecologic Oncologist, Australia Elisabeth Åvall Lundqvist, Medical Oncologist, Sweden Jaime Prat, Pathologist, Spain Shyam Shrivastava, Radiation Oncologist, India The Committee composition is likely to change during the 2015 FIGO World Congress when the report will be released, as members leave the committee after serving a six-year term. The composition of the new Committee will be announced by the incoming President of FIGO. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.